List of articles with "cancer therapies"

Innovent-Takeda Partnership

Innovent-Takeda Partnership

China Suzhou Innovent Biologics cancer therapies Takeda
Nuvalent Public Offering

Nuvalent Public Offering

United States Cambridge cancer therapies Nuvalent Class A Common Stock
Paul Blanchfield Joins Alpha-9

Paul Blanchfield Joins Alpha-9

USA Boston cancer therapies Alpha-9 Oncology Paul Blanchfield
Karyopharm Inducement Grants

Karyopharm Inducement Grants

United States XPOVIO cancer therapies Newton Karyopharm Therapeutics
Intensity Raises $4 Million

Intensity Raises $4 Million

None cancer therapies stock offering Intensity Therapeutics
OncoC4 Secures $50M

OncoC4 Secures $50M

USA Rockville cancer therapies Series B Funding OncoC4
Growth of KAT6 Inhibitors

Growth of KAT6 Inhibitors

United States Las Vegas cancer therapies KAT6 Inhibitors Epigenetic Targets
VEGFR-2 Inhibitors

VEGFR-2 Inhibitors

USA Las Vegas oncology cancer therapies VEGFR-2 Inhibitors
CIT and IFLI Partner

CIT and IFLI Partner

United States cancer therapies Diamond Bar IFLI CIT Therapeutics
Karyopharm RSUs Announcement

Karyopharm RSUs Announcement

United States Karyopharm XPOVIO cancer therapies Newton, Massachusetts
Myosin's New Cancer Therapies

Myosin's New Cancer Therapies

USA Jupiter cancer therapies Glioblastoma Myosin Therapeutics
Growth in GPCR Therapies

Growth in GPCR Therapies

United States Las Vegas cancer therapies DelveInsight GPCR-Targeting
Cancer Therapies on Wall Street

Cancer Therapies on Wall Street

USA Vancouver cancer therapies Oncolytics Biotech Indaptus Therapeutics
Enda Moran Joins Solu

Enda Moran Joins Solu

United States Boston cancer therapies Solu Therapeutics Enda Moran
Acquisition by Concentra

Acquisition by Concentra

United States Boston cancer therapies Elevation Oncology Concentra Biosciences
Anna Berkenblit Joins TORL

Anna Berkenblit Joins TORL

USA Los Angeles cancer therapies TORL BioTherapeutics Anna Berkenblit
AVEO at ASCO 2025

AVEO at ASCO 2025

United States Chicago cancer therapies AVEO Oncology Tivozanib
Karyopharm at Jefferies

Karyopharm at Jefferies

United States New York Karyopharm XPOVIO cancer therapies
Intra-tumoral Cancer Growth

Intra-tumoral Cancer Growth

None cancer therapies DelveInsight Intra-tumoral
Karyopharm at 2025 Conference

Karyopharm at 2025 Conference

USA New York Karyopharm XPOVIO cancer therapies
Hanx Bio's Cancer Therapies

Hanx Bio's Cancer Therapies

United States Chicago cancer therapies Hanx Biopharmaceuticals Bispecific Antibodies
Mabwell's Drug Innovations

Mabwell's Drug Innovations

China Shanghai cancer therapies ADCs Mabwell
ImmunoGenesis at NeauxCancer

ImmunoGenesis at NeauxCancer

United States New Orleans cancer therapies ImmunoGenesis NeauxCancer
Myosin Therapeutics Funding

Myosin Therapeutics Funding

United States Jupiter cancer therapies Clinical Trials Myosin Therapeutics
Syndax Inducement Grants

Syndax Inducement Grants

United States cancer therapies Waltham Syndax Pharmaceuticals SNDX
Ascentage Pharma at JPM 2025

Ascentage Pharma at JPM 2025

USA San Francisco Ascentage Pharma cancer therapies J.P. Morgan Conference
Brendan Strong Joins Karyopharm

Brendan Strong Joins Karyopharm

USA Karyopharm cancer therapies Brendan Strong Newton, Massachusetts
Cancer Therapy Access

Cancer Therapy Access

United States Boston cancer therapies Outcomes4Me CURE Media Group
Nuvalent at Healthcare Conf.

Nuvalent at Healthcare Conf.

United States healthcare Cambridge cancer therapies Nuvalent
Karyopharm at Healthcare Conf.

Karyopharm at Healthcare Conf.

United States New York Karyopharm XPOVIO cancer therapies

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.